Drug Trial Radar · NCT05937750
A Long-term Follow-up Trial of Patients Previously Treated With Imlifidase Prior to Kidney Transplantation and a Non-comparative Transplanted Patient Group
Last checked: Nov 19, 2026Latest source record: Jun 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Jul 3, 2023
Primary completion
Apr 30, 2030
Study completion Apr 30, 2030
Sponsor
- Lead sponsor
- Hansa Biopharma ABIndustry
- Sponsor type
- Industry
- First posted
- Jul 10, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years, up to 76 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A prospective, post-authorisation long-term follow-up trial of patients previously treated with imlifidase prior to kidney transplantation, including a non-comparative concurrent reference cohort.
Conditions
- Long Term Efficacy and Safety
Interventions
Imlifidase administered in the 20-HMedIdeS-19 (PAES) studyDrug
Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc-fragment and efficiently neutralizes Fc-mediated activities of IgG.
Best available treatment administered in the 20-HMedIdeS-19 (PAES) studyOther
Normal transplantation routine Transplantation and pre- and post-transplantation therapies in accordance with the clinic's normal transplantation routine.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Graft failure-free survival (%) up to 5 years after imlifidase enabled transplantation (imlifidase cohort only)Time frame: 5-years after transplantation
Locations
14 sites in 7 countries. Site status is shown where the registry gives one.
Medizinische Universitaet Wien
Vienna, Austria
Nephrology Clinic Vídeňská 1958/9
Prague, Czechia
Hôpital Necker - Enfants Malades
Paris, France
Centre Hospitalier Universitaire (CHU) de Rouen - Hôpital de Bois-Guillaume
Bois-Guillaume, Normandy, France
Azienda Ospedaliera di Padova
Padova, Italy
Azienda Ospedaliero - Universitaria di Parma
Parma, Italy
Leiden University Medical Center
Leiden, Netherlands
Erasmus University Medical Center
Rotterdam, Netherlands
Hospital Del Mar, Servicio de Nefrología
Barcelona, Spain
Hospital Universitario del Vall d´Hebron
Barcelona, Spain
Unidad de Trasplante Renal
Barcelona, Spain
Hospital Universitario 12 De Octubre
Madrid, Spain
Uppsala University Hospital
Uppsala, Sweden
Karolinska University Hospital,
Huddinge, Stockholm County, Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.